Skip to main content

The Alberta government is joining a class-action lawsuit to recoup health-care costs related to the opioid crisis, the province’s health minister said Tuesday.

Tyler Shandro said there were almost 800 fatal overdoses and 4,200 emergency calls related to opioids in the province last year alone.

“Albertans have paid a high price for the irresponsible actions of opioid manufacturers and distributors,” Mr. Shandro said.

Story continues below advertisement

“While we cannot bring back those we have lost, we can recover some of the enormous financial costs Albertans have paid and continue to pay.”

The British Columbia government filed the proposed class-action suit a year ago, alleging drug manufacturers falsely marketed opioids as less addictive than other pain drugs, helping to trigger a crisis that has killed thousands.

The suit seeks costs from those manufacturers and distributors dating back to 1996, when the pain drug OxyContin was introduced in the Canadian market.

None of the allegations in the lawsuit has been tested in court.

Ontario and Newfoundland previously announced they are also joining the suit.

B.C. Justice Minister David Eby said the claim is national in scope and all provinces have offered their support so far, despite their differences.

“We’ve had our challenges with Alberta on different issues,” Mr. Eby said. “But the fact that we can continue to work together on shared issues of priority like the harms caused by opioids, this is how Canada works.”

Story continues below advertisement

Mr. Shandro said opioids were being overprescribed by doctors in Alberta, and it’s important manufacturers also be held accountable.

“One of the main reasons doctors overprescribed is the companies told them that the opioids are safe. The manufacturers aggressively promoted the claim that opioids posed a low risk of addiction and that was misleading,” Mr. Shandro said.

“And second, we’re suing the companies because they oversupplied the drugs recklessly. They ignored evidence that the drugs were being overprescribed and diverted.”

Alberta spends $53-million a year on health care connected to opioids and is planning to spend an additional $40-million.

Alberta Justice Minister Doug Schweitzer said the province is also looking at bringing in legislation, similar to B.C.’s Opioid Damages and Health Care Costs Recovery Act, to allow for the recovery of health costs.

“We must not just watch out for individual crimes but also large entities who pose a threat to our health, safety and peddle in misery and human despair,” Mr. Schweitzer said.

Story continues below advertisement

In Edmonton, the NDP critic for mental health and addictions said the lawsuit is the right thing to do, but urged the government not to lose sight of other methods of alleviating the opioid problem while the legal wheels turn.

“This lawsuit is going to take a long time before we’ll see anything happen,” Heather Sweet said. “We’re urging the government to continue to address the opioid crisis today and not wait until this lawsuit is finalized.”

An Oklahoma court ruling in August found Johnson & Johnson helped fuel the state’s opioid crisis and ordered the company to pay US$572-million.

Purdue Pharma, the maker of the OxyContin, filed for bankruptcy in the United States and proposed a multibillion-dollar plan to settle with thousands of state and local governments.

Mr. Eby said the lawsuit is back in B.C. court Nov. 15, when the province will be adding the Sackler family, who owns Purdue Pharma, as a defendant.

Mr. Eby said he wants to ensure Purdue and other opioid manufacturers and distributors are not selling their Canadian assets to pay for a settlement for Americans.

Story continues below advertisement

“The Canadian assets should be going to compensate Canadians and Canadian families for what’s happened here.”

He said Canada is the world’s second-largest opioid market, but has been excluded from what is intended to be a global settlement.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies